Strategy

Today’s ailing economy has corporations and consumers alike demanding higher value for lower cost, and pharmaceuticals are no exception. In a recent Pharmaceutical Executive article, Monitor Partner Thomas Nagle offers three pricing models designed to optimize revenue without compromising patient care.

From financial services to manufacturing to consumer goods, executives report that growing profits in today’s competitive markets has become an ever more difficult task.

Remote Health Services (RHS) allow the patient to be treated wherever he/she is or chooses to be. Instead of having to take a trip to a doctor's office or hospital to be diagnosed and treated by trained  professionals, they come to him/her, virtually, thanks to the advances in information technology and telecommunications.

Telemedicine is poised to create a significant impact on the way patients are diagnosed, monitored and treated. It is also going to play an important role in keeping the population healthy in the future.

By 2010, customized medicare of some meaningful kind, will in all likelihood, become a reality.

Today’s buying process is a constantly changing ecosystem of multiple channels, greater competition and progressively empowered consumers. In their Marketing Management article, Monitor’s Mark Pocharski and Sheryl Jacobson help marketers develop the tools necessary to navigate the increasingly complex minds of consumers.

Everywhere you go business people are asking the same questions about
Internet commerce. Why are profits scarce or nonexistent? Why is there so
much uncertainty about Internet business models? When will some modicum
of order emerge from the chaos of doing business on the Web?

Sustained profitability is the bottom-line for every business, and key to achieving it is the ability to respond strategically to competition. In his Harvard Business Review article, Monitor founder Michael E. Porter details five competitive forces that influence profitability.

The antithesis of a traditional business model, biotechnology company Maxygen is the poster child for a new “biomolecular” way of organizing enterprise. Monitor’s Chris Meyer and Joan Chu analyze Maxygen’s paradigm – and question its sustainability – in their The Journal of Life Sciences article.

Scenario Thinking for Business Executives and Corporate Boards.

Businesses increasingly realize that significant growth opportunities are unlikely to come from incremental change.

Changes in the economic and political environment present many challenges to chemical companies today.

There's something wrong with the way companies are managed today.

Growing your core business doesn’t require a silver bullet, just the discipline of employing the tried and true growth principles.